Morgan joined the T1D Fund as an Associate in October 2024. Prior to joining the Fund, she received her PhD from MIT, where she was an NSF Fellow in the lab of Samir Mitragotri. Her thesis research focused on using simple, bioinspired materials for vaccine delivery.

She previously held fellowships at MPM Capital, where she worked on therapeutics company ideation, and Artis Ventures, where she conducted due diligence on early-stage biotech and healthcare companies. She received a BS in Bioengineering from the University of Maryland, College Park with a research focus on tissue engineering and biomaterials.

Valerie joined the T1D Fund in August 2024. Prior to joining the Fund, she worked at Sanofi as a Scientist, driving early drug discovery projects for autoimmune diseases using various modalities, including antibodies, small molecules, and NANOBODY® molecules. She also completed a 6-month internal internship in External Innovation, where she identified the current challenges and competitive landscape for transplant innovative therapies and prioritized the external opportunities in line with Sanofi’s portfolio.

Valerie completed her Ph.D. in Pharmacology at Yale University in the laboratory of David Calderwood, where she studied molecular regulators of integrin and cerebral cavernous malformation signaling pathways. Valerie received her B.A. in Molecular and Cell Biology from the University of California, Berkeley.